NCT00091624View on ClinicalTrials.gov

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

CC-5013

Trial Locations (1)

44195

Cleveland Clinic Myeloma Program, Cleveland

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY